Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator

被引:38
|
作者
Priviero, FBM [1 ]
Baracat, JS [1 ]
Teixeira, CE [1 ]
Claudino, MA [1 ]
De Nucci, G [1 ]
Antunes, E [1 ]
机构
[1] UNICAMP, Fac Med Sci, Dept Pharmacol, BR-13084971 Campinas, SP, Brazil
关键词
aorta; BAY; 41-2272; IH-[1,2,4]oxadiazolo[4, 3-a]quinoxalin-1-one; nitric oxide; sildenafil; soluble guanylate cyclase;
D O I
10.1111/j.1440-1681.2005.04262.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The compound BAY 41-2272 (5-cyclopropyl-2-[1-(2fluoro-benzyi)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4- ylamine) has been described as a potent, nitric oxide (NO)independent, stimulator of soluble guanylate cyclase. In the present study, the mechanisms underlying the relaxant effect of BAY 41-2272 in endothelium-intact and -denuded precontracted rabbit aortic rings were investigated. 2. Male New Zealand white rabbits were anaesthetized with pentobarbital sodium. Aortic rings were transferred to 10 mL organ baths containing oxygenated and warmed Krebs' solution. Tissues were connected to force-displacement transducers and changes in isometric force were recorded. Aortic rings were precontracted submaximally with phenylephrine (1 mu mol/L). 3. The addition of BAY 41-2272 (0.01-10 mu mol/L) to the organ bath produced concentration-dependent relaxations of the aortic rings with a higher potency in endothelium-intact (pEC(50) 6.59 +/- 0.05) compared with endothelium-denuded (pEC(50) 6.19 +/- 0.04; P < 0.05) preparations. No differences in maximal responses were observed in either preparation. The NO synthesis inhibitor N-G-nitro-L-arginine methyl ester (100 mu mol/L) produced a 2.1-fold rightward shift in endothelium-intact (P < 0.01) rings, but had no effect in endothelium-denuded rings. The soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 1 mu mol/L) caused significant rightward shifts of the concentration-response curves to BAY 41-2272 of 4.9- and 2.6-fold in endothelium-intact and -denuded rings, respectively. The phosphodiesterase-5 inhibitor sildenafil (0.1 mu mol/L) significantly potentiated the relaxant effects of BAY 41-2272 in both endothelium-intact and -denuded rings. 4. At 1 mu mol/L, BAY 41-2272 significantly elevated the aortic cGMP content above basal levels in both endothelium-intact and -denuded rings. Furthermore, ODQ reduced BAY 41-2272-elicited increases in cGMP content by 17 and 90% in endothelium-intact and -denuded rings, respectively (P < 0.01). 5. In conclusion, BAY 41-2272 potently relaxes endothelium-intact and -denuded rabbit aortic rings. The basal release of endothelium-derived NO enhances BAY 41-2272-induced relaxations, suggesting a synergistic effect of BAY 412272 and NO on soluble guanylate cyclase. In addition, the endothelium-independent relaxation involves both GMP-dependent and -independent mechanisms.
引用
收藏
页码:728 / 734
页数:7
相关论文
共 50 条
  • [31] Attenuated vasorelaxing activity to the nitric oxide-independent soluble guanylate cyclase activator YC-1 in eNOS deficient mouse aorta
    Li, DC
    Berkowitz, DE
    Mo, ZI
    Johns, RA
    ANESTHESIOLOGY, 2000, 93 (3A) : U168 - U168
  • [32] Binding of YC-1/BAY 41-2272 to soluble guanylate cyclase: A new perspective to the mechanism of activation
    Pal, Biswajit
    Kitagawa, Teizo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 397 (03) : 375 - 379
  • [33] BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase
    Koglin, M
    Stasch, JP
    Behrends, S
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 292 (04) : 1057 - 1062
  • [34] Nitric oxide-independent activation of soluble guanylate cyclase: From bench to bedside
    Stasch, Lohannes-Peter
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2008, 19 : S31 - S32
  • [35] THE ROLE OF SOLUBLE GUANYLATE CYCLASE STIMULATOR BAY 41-2272 ON REMODELLING PROCESSES RELEVANT TO THE PATHOGENESIS OF PULMONARY ARTERIAL HYPERTENSION
    Shao, D.
    Wort, S. J.
    THORAX, 2014, 69 : A22 - A23
  • [36] Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis
    Knorr, Andreas
    Hirth-Dietrich, Claudia
    Alonso-Alija, Cristina
    Haerter, Michael
    Hahn, Michael
    Keim, Yvonne
    Wunder, Frank
    Stasch, Johannes-Peter
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2008, 58 (02): : 71 - 80
  • [37] Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator
    Nakane, Masaki
    Kolasa, Teodozyi
    Chang, Renjie
    Miller, Loan N.
    Moreland, Robert B.
    Brioni, Jorge D.
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 102 (02) : 231 - 238
  • [38] Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum
    Baracat, JS
    Teixeira, CE
    Okuyama, CE
    Priviero, FBM
    Faro, R
    Antunes, E
    De Nucci, G
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 477 (02) : 163 - 169
  • [39] Oxidative Stress Impairs Vasorelaxation Induced by the Soluble Guanylyl Cyclase Activator BAY 41-2272 in Spontaneously Hypertensive Rats
    Priviero, Fernanda B. M.
    Zemse, Saiprasad M.
    Teixeira, Cleber E.
    Webb, R. Clinton
    AMERICAN JOURNAL OF HYPERTENSION, 2009, 22 (05) : 493 - 499
  • [40] Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure
    Boerrigter, G
    Costello-Boerrigter, LC
    Cataliotti, A
    Tsuruda, T
    Harty, GJ
    Lapp, H
    Stasch, JP
    Burnett, JC
    CIRCULATION, 2003, 107 (05) : 686 - 689